Stocks · News reference
Quanterix (NASDAQ:QTRX) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.46) by 2.17 percent. This is unchanged from the same period last year. The company reported
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Quanterix is hosting a multi-speaker webinar focused on the integration of spatial proteomics and spatial transcriptomics to enhance biological insights from tissue samples.
TD Cowen analyst Dan Brennan maintains Quanterix (NASDAQ:QTRX) with a Hold and raises the price target from $3 to $3.5.
Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, and Innovita Biological Technology Co., Ltd. (SSE: 688253.SH), a leading in vitro diagnostics company in China, today announced
The global Alzheimer's disease biomarker market is projected to grow from USD 2.2 billion in 2025 to USD 4.7 billion by 2034, driven by rising disease prevalence, aging populations, and advancements in blood-based biomarkers like phosphorylated tau and amyloid-beta assays. North America leads the market with 41% share, while Asia-Pacific is the fastest-growing region. Recent FDA clearances and expanded laboratory testing availability are accelerating market adoption.